TYK2

Across TCGA pan-cancer cohorts, TYK2 Mutation is linked to patient survival in 12 of 34 cancer types, making it a survival-associated TYK2 data layer compared with 26 for mass-spec protein and 4 for mass-spec protein.

The strongest signal is observed in adrenocortical carcinoma (ACC), where higher TYK2 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated TYK2 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

ACC, LUAD, and BRCA are the cancer types where TYK2 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
ACC	DFS	Median	All	0.046	0.753	<.001	36	view →
LUAD	DFS	Median	All	0.368	0.771	<.001	32	view →
BRCA	OS	Median	All	0.171	0.582	<.001	32	view →
UCEC	DFS	Median	All	0.823	0.629	.014	10	view →
OV	OS	Median	III,IV	0.289	0.683	.026	6	view →
CESC	DFS	Median	III,IV	0.240	0.726	.015	6	view →
KIRC	OS	Median	All	0.290	0.632	.017	4	view →
CHOL	OS	Median	All	0.155	0.725	.029	3	view →
ESCA	DFS	Median	All	0.195	0.535	.039	3	view →
LIHC	OS	Median	All	0.313	0.690	.044	3	view →
LGG	OS	Median	All	0.551	0.911	.008	2	view →
LUSC	DFS	Median	All	0.375	0.649	.048	2	view →

Pink = unfavorable, green = favorable. Showing the 12 strongest of 12 lineages.

TYK2–ACC (DFS)

Open the ACC breakdown →